Leukemoid reactions are defined by marked leukocytosis not caused by hematologic malignancy. Most studies have used a threshold higher than 25 × 10^9/L to define these events, but the authors emphasized that no single, universally accepted cut-off exists; clinicians must assess counts in clinical context. Case series suggest these reactions are uncommon—reported in about 0.5% to 1% of hospitalized adults—but when they occur the outcomes can be poor. Investigators reported overall in-hospital mortality approaching 40%, and mortality may be nearly 60% in patients whose leukemoid reaction lasts more than one day. The study team observed that death is frequently driven by the underlying illness and its complications, including end-organ injury and multiorgan failure, rather than by leukocytosis alone.
Infection is the most common precipitant. The authors specifically named Clostridioides difficile infection and tuberculosis among notable infectious causes. Noninfectious causes were described as diverse: exposure to granulocyte colony-stimulating factor and systemic corticosteroids can provoke marked leukocytosis, as can metastatic carcinomatosis with bone marrow involvement (often presenting as a leukoerythroblastic picture). Surgery, major trauma and hemorrhage were listed as triggers. Systemic inflammatory conditions may also cause leukemoid reactions. The article recommended that history and physical examination guide targeted investigations for these potential causes. The authors also cautioned that leukemoid reactions can coexist with underlying myeloid neoplasms, so reactive and neoplastic processes are not mutually exclusive.
Peripheral smear examination often provides the earliest clues. Typical findings in leukemoid reactions include marked neutrophilia, a left shift with increased immature granulocytes and rare or absent circulating blasts. Toxic granulations and Döhle bodies may be present; thrombocytosis can accompany the white cell rise. The study team noted that certain patterns—specifically eosinophilia, basophilia or monocytosis—lean the differential toward a hematologic malignancy rather than a pure reactive process. Investigators cited manual smear review as useful in distinguishing reactive changes from features more suggestive of leukemia.
Reactive leukocytosis can mimic chronic myelogenous leukemia (CML) and chronic neutrophilic leukemia clinically and morphologically. The authors recommended that, after reasonable investigation for secondary causes, testing for the BCR-ABL1 fusion gene be performed to exclude CML. They reported that urgent hematology consultation is warranted for patients with certain red flags: palpable splenomegaly, a leukocyte count exceeding 100 × 10^9/L, an increased proportion of circulating blasts, morphologic dysplasia on smear or persistent leukocytosis despite treatment of identified secondary causes.
Most cohorts have used a leukocyte threshold greater than 25 × 10^9/L to designate a leukemoid reaction, but the authors reiterated that this is a convention rather than an evidence-derived universal standard. Clinical judgment should guide interpretation: the tempo of the rise, associated signs (fever, hemodynamic instability, organ dysfunction), and peripheral smear morphology all matter. The paper supplied concrete consult triggers: splenomegaly, leukocyte counts >100 × 10^9/L, elevated blasts, morphologic dysplasia and lack of response to treatment for secondary causes—each of these should prompt urgent hematology input.
The authors acknowledged gaps in consensus. No single leukocyte cut-off is accepted universally, and the decision threshold depends on the clinical context; the source did not report a new diagnostic algorithm or specific management protocols. Much of the evidence cited comes from case series and cohort reports, and the article did not provide randomized data on interventions directed at leukocytosis itself. Prognosis appears to be tied primarily to the underlying disorder rather than the leukemoid reaction per se, but how best to risk-stratify individual patients with severe leukocytosis remains unclear. Specific unanswered questions documented in the source include how to standardize diagnostic thresholds across populations and whether targeted interventions for leukocytosis alter outcomes beyond treating the inciting condition. These gaps frame practical next steps: careful history and exam, prompt smear review, molecular testing for BCR-ABL1 when indicated, and early hematology consultation for the high-risk features described above.